Catalog No.
Product Name
Application
Product Information
Citations
-
FAAH Inhibitor
AZ513 is a reversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 551 nM for human FAAH and 27 nM for rat FAAH. This compound effectively inhibits the hydrolysis of anandamide in human FAAH-transfected HEK293 cells, demonstrating an IC50 of 360 nM. AZ513 is suitable for research applications focusing on the modulation of endocannabinoid signaling pathways and the study of pain relief and neuroprotection mechanisms. -
FAAH Inhibitor
PHOP is a selective inhibitor of fatty acid amide hydrolase (FAAH), utilized in fluorometric assays to evaluate inhibitory activity. It effectively quantifies FAAH activity by detecting the release of 4-pyridin-1-ylbutyric acid in rat brain microsomes. PHOP's capability for direct measurement of FAAH activity through reversed-phase HPLC and fluorescence detection supports its potential as a foundational tool in the development of novel FAAH inhibitors. This reagent is instrumental in fatty acid signaling research and related therapeutic investigations. -
Factor Xa Substrate
CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate specifically designed for the enzymatic activity of Factor Xa. Upon cleavage by Factor Xa, it releases p-nitroaniline, which can be quantitatively measured to assess enzymatic function. This compound is valuable for studies involving coagulation cascades and is commonly used in research applications focused on thrombosis and hemostasis. -
Factor Xa
Bovine Factor Xa is a trypsin-like serine protease that plays a critical role in the coagulation cascade, facilitating thrombin generation. This enzyme is commonly used in research applications related to blood coagulation, hemostasis, and thrombolysis. Its ability to activate prothrombin into thrombin makes it valuable for studies aiming to understand clot formation and regulation. -
Thrombin/ Factor Xa Inhibitor
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis. -
Factor Xa Inhibitor
Dechloro Rivaroxaban is a potent, selective inhibitor targeting Factor Xa, demonstrating a Ki of 0.4 nM against human free FXa. This compound effectively inhibits prothrombinase activity and fibrin-associated FXa activity, exhibiting IC50 values of 2.1 nM and 92 nM, respectively. Dechloro Rivaroxaban is suitable for research applications focused on coagulation and antithrombotic drug development. -
Thrombin/Factor Xa Inhibitor
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies. -
Factor Xa Inhibitor
Edoxaban impurity 6 is a chemical impurity associated with Edoxaban, a selective and potent oral inhibitor of factor Xa (FXa). It exhibits binding affinities with Kis of 0.561 nM for free FXa and 2.98 nM for prothrombinase, highlighting its significant role in anticoagulation. Research applications include studying the pharmacokinetics and safety profiles of FXa inhibitors, particularly in the context of stroke prevention and thromboembolic disorders. -
Factor Xa Inhibitor
Fidexaban is a potent Factor Xa inhibitor that plays a significant role in the modulation of the coagulation cascade. It is primarily utilized in cardiovascular disease research, providing valuable insights into thrombotic disorders and potential therapeutic strategies. Its mechanism of action contributes to the understanding of anticoagulant therapies and their implications in various pathological conditions. -
Factor Xa Inhibitor
FXIa-IN-7 is a selective, orally bioavailable inhibitor of Factor XIa, exhibiting an impressive IC50 value of 0.4 nM. This compound demonstrates potent antithrombotic potential, making it a valuable tool for research in coagulation pathways and thrombotic disorders. Its specificity towards Factor XIa positions FXIa-IN-7 as an important reagent for studies aimed at understanding the role of the intrinsic pathway in hemostasis and thrombosis. -
Factor Xa Inhibitor
Betrixaban hydrochloride is a highly potent and selective inhibitor of factor Xa (fXa), exhibiting an IC50 of 1.5 nM. This compound demonstrates significant antithrombotic activity, making it valuable for research applications focused on thrombosis and coagulation disorders. Betrixaban hydrochloride is suitable for studies investigating novel anticoagulant therapies and the mechanistic pathways of blood clotting. -
Factor Xa Inhibitor
Razaxaban hydrochloride is a selective and potent inhibitor of factor Xa, exhibiting a Ki of 0.19 nM. With over 5000-fold selectivity for factor Xa compared to other serine proteases, this compound effectively impedes the coagulation cascade. Additionally, Razaxaban hydrochloride displays thrombin inhibition with a Ki value of 540 nM, underscoring its significant antithrombotic properties. It is a valuable tool for research into anticoagulation therapies and the modulation of thrombotic disorders. -
Factor Xa Inhibitor
EMD 495235 is a potent and orally active inhibitor of coagulation factor Xa, exhibiting an IC50 of 5.5 nM and a Ki of 6.8 nM. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and hemostasis. EMD 495235 can be utilized to investigate the mechanisms of coagulation and evaluate potential therapeutic strategies for related disorders. -
Factor Xa Inhibitor
FXIa-IN-6 is a highly selective inhibitor of Factor XIa, demonstrating a Ki value of 0.3 nM. This compound is integral in studying the coagulation cascade and serves as a valuable tool in thrombosis research. Its ability to specifically target Factor XIa provides insights into potential therapies for clotting disorders while minimizing cross-reactivity with other serine proteases. -
Factor Xa Inhibitor
FXIa-IN-13 is a selective inhibitor of Factor Xa, displaying significant antithrombotic activity. This compound effectively inhibits arteriovenous thrombosis in both in vivo and in vitro models, making it a valuable tool for research on thrombosis and coagulation disorders. Its application in studying the mechanisms of blood clotting can provide insights into therapeutic strategies for cardiovascular diseases. -
Factor Xa Inhibitor
EMD-503982 is an orally bioavailable inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By selectively inhibiting Factor Xa, this compound effectively reduces thrombin generation, making it a valuable tool in research focused on thrombosis and coagulation disorders. Its utility in various biological assays and preclinical studies further supports investigations into anticoagulant therapies and related cardiovascular research. -
Coagulation Factor Xa Inhibitor
L-Guluronic acid is a coagulation Factor Xa inhibitor that retains the inhibitory activity against Factor Xa while serving as a substitute for L-Iduronic acid in anticoagulant pentasaccharides derived from heparin-like substances. Its capacity to modulate coagulation processes makes it valuable in research focused on coagulation disorders, including deep vein thrombosis and pulmonary embolism. This compound facilitates the exploration of therapeutic strategies aimed at managing these significant vascular conditions. -
Factor Xa Inhibitor
RPR 130737 is a selective and potent competitive inhibitor of Factor Xa, exhibiting an inhibition constant (Ki) of 2.4 nM. This compound demonstrates over 1000-fold selectivity against thrombin, activated protein C, plasmin, tissue-plasminogen activator, and trypsin, making it an ideal tool for cardiovascular research. RPR 130737 effectively prolongs both activated partial thromboplastin time and prothrombin time while having no impact on platelet aggregation. It is primarily utilized in studies relating to thrombotic disorders and cardiovascular diseases. -
Factor Xa Inhibitor
RPR-208707 is a selective inhibitor of Factor Xa, exhibiting a Ki of 18 nM. This compound demonstrates significant anti-thrombotic activity, making it a valuable tool for research focused on thrombosis-related diseases. Its specificity for Factor Xa positions it as a potent candidate for exploring mechanisms of coagulation and potential therapeutic interventions in thrombotic disorders. -
Thrombin/Factor Xa Inhibitor
Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy. -
Thrombin/Factor Xa/Trypsin/Papain Inhibitor
Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research. -
Factor Xa Inhibitor
(1R,2R,4R)-Edoxaban is a selective inhibitor of activated coagulation factor X (Factor Xa). It demonstrates potent anticoagulant activity, making it a valuable tool in the study of thrombosis and related cardiovascular conditions. This reagent is suitable for researching mechanisms of coagulation and evaluating therapies aimed at managing thromboembolic disorders. -
Factor Xa Inhibitor
BI-11634 is a potent factor Xa inhibitor that plays a critical role in anticoagulant research. It is primarily metabolized by the enzyme CYP3A4, leading to the formation of a major metabolite. The metabolism of BI-11634 can be inhibited by Quinidine, demonstrating a Ki value of 7 µM, indicating its potential importance in studies related to drug interactions and cardiovascular therapeutics. -
Factor Xa Inhibitor
Darexaban glucuronide is an active metabolite of darexaban, functioning as a potent inhibitor of Factor Xa. This compound exhibits significant oral bioactivity and demonstrates antithrombotic effects, making it valuable for research into thromboembolic disorders. Its properties support studies focused on anticoagulant therapies and the mechanistic understanding of coagulation pathways. -
Factor Xa Inhibitor
AS1468240 is a potent, orally active inhibitor of factor Xa (fXa), demonstrating an IC50 of 8.7 nM against human fXa. This compound effectively prolongs coagulation time in murine models, highlighting its potential as an anticoagulant agent. It serves as a valuable tool for research into coagulation pathways and the development of therapeutic strategies for thromboembolic disorders. -
Factor Xa Inhibitor
Tanogitran is a dual inhibitor that targets Factor Xa and thrombin, exhibiting Ki values of 26 nM and 2.7 nM, respectively. This compound demonstrates significant anticoagulant activity, making it valuable for research in thrombotic diseases and related cardiovascular studies. Researchers can utilize Tanogitran to investigate the mechanisms of coagulation and the potential therapeutic applications in anticoagulation therapy. -
Endogenous Metabolite
SU200 is a TRPV1 agonist that modulates intracellular calcium ion concentrations. It induces distinct calcium ion response patterns, displaying notable reactivity and peak efficacy. The effects of SU200 exhibit varying degrees of response delay and variability across different cell types. This compound offers potential avenues for pharmacological development and further research into calcium signaling pathways. -
Endogenous Metabolite
RO5101576 is a potent antagonist of the leukotriene B4 (LTB4) receptor, effectively inhibiting LTB4-induced calcium mobilization and chemotaxis in human neutrophils. This compound demonstrates significant reduction of LTB4-induced pulmonary eosinophilia in guinea pigs, and it inhibits allergen- and ozone-induced pulmonary neutrophilia in nonhuman primates with efficacy similar to that of budesonide. Notably, RO5101576 does not affect LPS-induced neutrophilia in guinea pigs or cigarette smoke-induced neutrophilia in mice and rats. Its favorable performance in toxicology studies indicates good tolerability. -
Endogenous Metabolite
(R)-Pioglitazone-d1 is a deuterated form of the R-enantiomer of pioglitazone, primarily targeting mitochondrial function and exhibiting non-steroidal anti-inflammatory properties. This compound is significant for research applications related to non-alcoholic steatohepatitis (NASH) treatment, as it supports glucose modulation and enhances metabolic activity. Its stable isotopic labeling enables detailed metabolic studies and mechanistic investigations in related biological systems. -
Endogenous Metabolite
l-Primaquine is an antimalarial compound primarily targeting the elimination of Plasmodium species. It exhibits significant activity in the prevention and treatment of malaria infections, as well as providing therapeutic benefits against Pneumocystis jiroveci pneumonia. This endogenous metabolite is valuable in both clinical and research settings for studying malaria and related diseases. -
Fungal Metabolite
Methyl 3,4,5-trimethoxy-2-(2-(nicotinamido)benzamido)benzoate is a fungal metabolite that acts as a target for various biological interactions. This compound exhibits significant antifungal activity, making it a valuable reagent for research in microbiology and pharmacology. It is particularly useful for studies focused on fungal infections and the exploration of novel therapeutic agents derived from natural sources. -
Endogenous Metabolite
Lead salicylate is an endogenous metabolite that primarily acts as an anti-inflammatory agent. Its biological activity includes inhibition of cyclooxygenases (COX-1 and COX-2), which are key enzymes involved in the synthesis of prostaglandins. This compound is often used in research to investigate mechanisms of inflammation and the modulation of pain pathways, contributing to a better understanding of inflammatory diseases and potential therapeutic strategies. -
Endogenous Metabolite
VU0415374 is a positive allosteric modulator of the mGlu4 receptor, enhancing its activity and enabling precise manipulation of physiological responses. This compound exhibits high selectivity, making it a valuable tool for investigating the role of mGlu4 in conjunction with other mGlu receptor systems. Its refined properties position VU0415374 as a significant candidate for experiments requiring high spatial and temporal precision in mGlu4 research. -
Fungal Metabolite
6-Ethyl-2,7-dimethoxyjuglone is a fungal metabolite known for its biological activity against various pathogens. This compound has been isolated from freshwater fungi and exhibits potential antifungal properties. It serves as a valuable tool for research applications focusing on fungal biology and the discovery of new antifungal agents. -
Endogenous Metabolite
1,2-Dipentadecanoyl-rac-glycerol is an endogenous metabolite that primarily targets cellular lipid metabolism. This compound has been studied for its role in insulin-mediated regulation of 1,2-diacylglycerol levels in rat hearts, highlighting its potential implications in cardiac contractility. Its distinct fatty acid composition may provide insights into the metabolic pathways influenced by insulin, making it a valuable tool for research in cardiovascular physiology and metabolic disorders. -
Endogenous Metabolite
4-Acetylaminobutanal is an endogenous metabolite involved in the urea cycle. It serves as an important intermediate in amino acid metabolism and is significant for studying metabolic pathways and related disorders. Researchers can utilize 4-Acetylaminobutanal to explore its role in metabolic processes and the implications of urea cycle dysregulation in various biological systems. -
Endogenous Metabolite
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphoinositol functions as an endogenous metabolite and a critical component of cell membranes. This phosphoinositol plays a vital role in various cellular processes, including signal transduction and membrane dynamics. Its study is essential for understanding lipid metabolism, cellular signaling pathways, and membrane structure in biological research. -
Endogenous Metabolite
GYKI-16084 is an endogenous metabolite that can be isolated from canine and rodent urine. This compound exhibits potential relevance in studying benign prostatic hyperplasia, contributing to our understanding of urological health and disorders. Its utility in research makes it a valuable tool for exploring mechanisms underlying prostate-related conditions. -
Endogenous Metabolite
A 854777 is a homologous piperazine derivative that targets endogenous metabolites, exhibiting notable anti-inflammatory activity. This compound possesses non-classical immunosuppressive properties, making it valuable for studies focused on modulating immune responses. Its applications include research into diseases characterized by inflammation, providing insights into potential therapeutic interventions. -
Endogenous Metabolite
9-cis-Vitamin A palmitate is an endogenous metabolite and a 9-cis isomer derived from vitamin A palmitate, commonly found in dietary sources such as corn flakes. This compound exhibits approximately 26% of the biological activity compared to all-trans-vitamin A palmitate, the predominant and most active form of vitamin A. It serves as a valuable reagent for research focused on vitamin A metabolism, retinoid signaling pathways, and the development of therapies targeting retinoid-related disorders. -
Endogenous Metabolite
OMDM-3 is a selective inhibitor of anandamide cellular uptake (ACU), exhibiting a Ki value of 16.6 μM. This compound is metabolically stable, making it suitable for studies investigating the role of anandamide in cannabinoid signaling and endocannabinoid system modulation. OMDM-3 can be utilized in research applications focused on pain management, neuroprotection, and the exploration of lipid signaling pathways. -
Endogenous Metabolite
DF 461 is a selective sterol synthase inhibitor that effectively impairs cholesterol biosynthesis. Demonstrating high specificity for liver tissue, DF 461 significantly reduces cholesterol synthesis in rat liver models. This compound has also been shown to lower plasma lipid levels in repeated dosing studies in non-rodent species, making it valuable for research applications related to lipid metabolism and cardiovascular health. -
Endogenous Metabolite
UCM765 is a selective ligand for the MT2-type melatonin receptor, exhibiting hypnotic, analgesic, and anxiolytic activities. Its partial agonist properties make it a valuable compound for pharmacological research. Structural modifications of UCM765 can enhance its water solubility and metabolic stability, potentially increasing its bioavailability. The compound's biological effects have been substantiated in rat models, indicating its promise for further exploration in pharmacological studies. -
Endogenous Metabolite
Chondrosamine, 6-phosphate is an endogenous metabolite that plays a critical role in amino sugar metabolism. This amino sugar phosphate compound is involved in multiple biochemical pathways related to sugar metabolism. Its relevance in studying cellular metabolism and synthetic pathways makes it a valuable reagent for research applications in biochemistry and molecular biology. -
Endogenous Metabolite
TRIA-662 iodide, also known as 1-Methylnicotinamide chloride, is an endogenous metabolite that primarily targets pathways associated with inflammation and thrombosis. This compound exhibits notable antithrombotic and anti-inflammatory activities, making it valuable for research applications focused on cardiovascular health and inflammatory diseases. Its role in cellular metabolism further highlights its potential in studying metabolic dysregulation and related disorders. -
Endogenous Metabolite
β-Nicotinamide adenine dinucleotide reduced dipotassium (NADH) functions primarily as a key coenzyme in redox reactions. It serves as a donor of ADP-ribose units in ADP-ribosylation processes and is a precursor to cyclic ADP-ribose. Additionally, NADH plays a vital role in cellular energy metabolism, contributing to pathways such as glycolysis, β-oxidation, and the tricarboxylic acid (TCA) cycle, making it essential for various research applications in metabolic studies and cellular function analysis. -
Endogenous Metabolite
IST-622 is an endogenous metabolite exhibiting significant anti-tumor activity through the inhibition of cancer cell growth. It demonstrates potent growth inhibitory effects against various mouse tumor models, including P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, and Colon 26 and 38 adenocarcinomas. Additionally, IST-622 is effective in human tumor xenograft models, notably large cell lung carcinoma and gastric adenocarcinoma. In vitro studies reveal an IC50 for P388 leukemia that is over 20 times lower than conventional treatments, underscoring its potential as a therapeutic agent in oncology research. -
Endogenous Metabolite
GCN2iB acetate is a selective inhibitor of the GCN2 kinase, primarily targeting the Gcn2 signaling pathway. It enhances the phosphorylation of eIF2, leading to increased expression of Atf4, particularly in Gcn2 mutants with specific alterations in regulatory regions or kinase domain substitutions. This compound is valuable for studying cellular responses to nutritional stress and has potential applications in cancer research, specifically in sensitizing cancer cells with low levels of aspartate synthetase to the anti-leukemic agent L-aspartase. -
Endogenous Metabolite
1-Myristoyl-2-(4-nitrophenylsuccinyl)-sn-glycero-3-phosphocholine is a synthetic phospholipid that primarily targets cell membranes to inhibit cell proliferation. This compound serves as an effective carrier to enhance the bioavailability of various therapeutic agents. Additionally, it is an important tool in cell membrane research, facilitating the study of cell signal transduction pathways. -
Endogenous Metabolite
GNE-783 is a selective checkpoint kinase 1 (CHK1) inhibitor that plays a pivotal role in modulating the cell cycle response to DNA damage. By inactivating S-phase and G2-phase checkpoints, it enhances the efficacy of anti-metabolite chemotherapeutics, such as gemcitabine and temozolomide, particularly in melanoma cell lines. GNE-783 is instrumental in research applications focused on overcoming drug resistance and improving treatment outcomes across various tumor types.
